These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2572324)

  • 1. Effects of bunazosin on plasma glucose levels in hypertensive diabetic patients.
    Takeda N; Iwai T; Tanamura A; Nagano M
    Clin Ther; 1989; 11(5):568-71. PubMed ID: 2572324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of essential hypertension with the alpha-1 antagonist bunazosin retard. A multicenter, double-blind, placebo-controlled study].
    Kirsten R; Weidinger G
    Arzneimittelforschung; 1994 Jan; 44(1):13-6. PubMed ID: 7907871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review.
    Weidinger G
    Arzneimittelforschung; 1995 Nov; 45(11):1166-71. PubMed ID: 8929232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate.
    Al-Waili N
    Eur J Med Res; 2003 Jul; 8(7):295-303. PubMed ID: 12911866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
    Eriksson JW; Jansson PA; Foley K; Lithell H
    J Hypertens; 1996 Dec; 14(12):1469-75. PubMed ID: 8986932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia.
    Yashiro A; Sugano M; Nakashima Y; Tasaki H; Kuroiwa A
    Clin Ther; 1987; 10(1):98-106. PubMed ID: 2897239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enalapril on lipid profile in diabetic and non-diabetic essential hypertensive patients.
    Satia MC; Shukla ML; Goyal RK
    Indian J Physiol Pharmacol; 1996 Jan; 40(1):83-6. PubMed ID: 8864777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of bunazosin and propranolol on serum lipids and apolipoproteins in patients with essential hypertension.
    Sasaki J; Koga S; Uzawa H; Arakawa K
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):402-7. PubMed ID: 2676872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive and metabolic effects of nitrendipine in hypertensive diabetic patients.
    Giuntoli F; Galeone F; Gabbani S; Spagnolo G; Brunelleschi G; Natali A; Gallo Stampino C; Saba P
    Clin Ther; 1990; 12(5):421-6. PubMed ID: 2268864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics.
    Prince MJ; Stuart CA; Padia M; Bandi Z; Holland OB
    Arch Intern Med; 1988 Nov; 148(11):2363-8. PubMed ID: 2847668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects.
    Satia MC; Shukla ML; Goyal RK
    Indian J Physiol Pharmacol; 1995 Jul; 39(3):237-41. PubMed ID: 8550116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
    Shionoiri H; Gotoh E; Ito T; Hata T; Iwatsubo H; Takegawa K; Ogihara T; Mikami H; Ikegami H; Otsuka A
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S91-5. PubMed ID: 7908168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
    Yasuda G; Hasegawa K; Kuji T; Ogawa N; Shimura G; Umemura S; Tochikubo O
    Diabet Med; 2005 Oct; 22(10):1394-400. PubMed ID: 16176202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise testing of the chronic effects of bunazosin hydrochloride on dilated cardiomyopathy.
    Nakano A; Tamura M; Hatori M; Hasegawa A; Suzuki T; Murata K
    Arzneimittelforschung; 1989 Dec; 39(12):1590-2. PubMed ID: 2576205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM).
    Oren S; Turkot S; Paran E; Flandra O; Slezak L; Hof B
    J Hum Hypertens; 1996 Feb; 10(2):123-7. PubMed ID: 8867567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration/effect relationship of bunazosin, a selective alpha 1-adrenoceptor antagonist in hypertensive patients after single and multiple oral doses.
    Harder S; Thürmann P
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):38-43. PubMed ID: 7911057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of chronic prazosin treatment.
    Barbieri C; Ferrari C; Borzio M; Piepoli V; Caldara R
    Horm Metab Res; 1980 Jul; 12(7):331-4. PubMed ID: 6105121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
    Pasanisi F; Imperatore G; Vaccaro O; Iovine C; Ferrara LA
    Nutr Metab Cardiovasc Dis; 1999 Apr; 9(2):73-7. PubMed ID: 10726112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of the alpha 1-adrenergic antagonist bunazosin retard in hypertensives.
    Shionoiri H; Minamisawa M; Ueda S; Minamisawa K; Takizawa T; Takasaki I; Sugimoto K; Gotoh E; Ishii M
    Arzneimittelforschung; 1994 Nov; 44(11):1191-5. PubMed ID: 7848330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.